https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-announces-first-reported-revenue-following-successful-launch-of-lymphir-302687092.html
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
citius pharmaceuticals incfirst reportedannouncesrevenuefollowing
https://valueinvesting.io/CTXR/valuation/wacc
CTXR WACC, Cost of Equity, Cost of Debt and CAPM | Citius Pharmaceuticals Inc (CTXR)
The WACC of Citius Pharmaceuticals Inc (CTXR) is 8.1%. The Cost of Equity of Citius Pharmaceuticals Inc (CTXR) is 8.30%. The Cost of Debt of Citius...
cost of equitycitius pharmaceuticals incwaccdebtcapm
https://www.salamancapress.com/2024/12/27/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update/
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business...
Dec 28, 2024 - Clinical and regulatory success in 2024 expected to drive value in 2025
citius pharmaceuticals incfull yearfinancial resultsreportsfiscal
https://www.ldmicro.com/profile/ctxr/news/6406010434876760
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) :: LD Micro
Read this press release and other recent news about Citius Pharmaceuticals Inc. (CTXR) at ldmicro.com
citius pharmaceuticals incnasdaqldmicro